Disc Medicine: 2024 net loss $109.4M, bitopertin NDA on track H2 2025 via accelerated approval

Disc Medicine, Inc.

2024-FY EPS reported -$3.96

Full-year 2024 net loss $109.4M vs $76.4M in 2023; R&D expenses rose to $96.7M.
Cash $489.9M at year-end; plus $243.3M net from Jan 2025 offering, funds operations into 2028.
Bitopertin: FDA path to accelerated approval for EPP; NDA submission planned H2 2025.
DISC-0974: Phase 2 MF anemia trial initiated; initial data expected H2 2025.
DISC-3405: Phase 2 in polycythemia vera expected H1 2025; Phase 1 showed proof-of-mechanism.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.